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Abstract 
 
 
This thesis is based on the protein TAF 15. As a TATA binding protein associated 
factor it is part of the basal transcription factor TFIID, but also exhibits a variety of 
other functions as a member of the unique TET family. 
I found TAF 15 in a Tandem Affinity Purification Assay as an interaction partner for 
ISG 12. ISG 12 is a small interferon stimulated gene of approximately 12kDa 
localized in the nuclear membrane. It is speculated to be an inducible part of the 
nuclear pore complex. It is highly upregulated in atherosclerotic lesions and acts 
proinflammatory by decreasing the synthesis of antiinflammatory factors. This effect 
is achieved by an ISG 12 dependent export of nuclear receptors from the nucleus to 
the cytoplasm. 
I investigated complex formations between ISG 12, TAF 15 and nuclear receptors, 
especially NR4A1. TAF 15 was found to interact with ISG 12 and several nuclear 
receptors including NR4A1, PPARα and RXRα as well as the transcription factor 
p65. All of these factors were previously identified to interact with ISG 12. 
Additionally, ISG 12 was able to downregulate the transcriptional activity of all these 
factors significantly. 
Silencing of TAF 15 by siRNA ultimately led to a decreased complex formation 
between ISG 12 and the tested proteins. Furthermore, silencing of TAF 15 
abolished the export of NR4A1 to the cytoplasm, even when ISG 12 was 
overexpressed. Surprisingly, a knock out of TAF 15 led to a stronger signal in a 
fluorescence resonance energy transfer experiment, suggesting that TAF 15 is not 
actually necessary for ISG 12 to form complexes with nuclear receptors, but rather 
stabilizes them. 
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Zusammenfassung 
 
 
Diese Diplomarbeit beschäfftigt sich mit dem Protein TAF 15. Es gehört zu den 
TATA binding associated factors und ist somit ein Teil des Transkriptionsfaktors 
TFIID. Darüberhinaus erfüllt es noch eine Vielzahl anderer Funktionen als Mitglied 
der einzigartigen TET Familie. 
TAF 15 wurde in einem Tandem Affinity Purification Assay gefunden, als ein 
Interaktionspartner von ISG 12. Bei ISG 12 handelt es sich um ein kleines Interferon 
induziertes Gen. Das Protein hat eine Größe von ca. 12kDa und befindet sich in der 
Kernmembran. Weiters wird spekuliert, dass ISG 12 ein induzierbarer Teil der 
Kernpore sein könnte. In atherosklerotischen Lesionen wurde ISG 12 in 
überexpremierten Mengen gefunden, wo es proinflammatorisch wirkt indem es die 
Produktion von antiinflammatorischen Faktoren vermindert. Die Ursache für diesen 
Effekt liegt in einem ISG 12 abhängigen Export von nuklearen Rezeptoren aus dem 
Kern ins Zytoplasma. 
Aufgrund dessen untersuchte ich die Komplexbildung zwischen ISG 12, TAF 15 und 
nuklearen Rezeptoren, wobei mein Hauptaugenmerk NR4A1 galt. Die Ergebnisse 
zeigten eine Interaktion zwischen TAF 15 und ISG 12, sowie mit den nuklearen 
Rezeptoren NR4A1, PPARα und RXRα. Desweiteren wurde der 
Transkriptionsfaktor p65 als Interaktionspartner von TAF 15 identifiziert. Diese 
Proteine wurden in früheren Experimenten bereits als Interaktionspartner von ISG 
12 bestättigt. Zusätzlich hatte ISG 12 den gleichen negativ regulierenden Effekt auf 
die Transkriptionsaktivität dieser Faktoren. 
Die Herunterregulierung von TAF 15 mittels siRNA führte zu einer verminderten 
Komplexbildung zwischen ISG 12 und den vorher genannten Proteinen. Weiters 
verhinderte die Herunterregulierung von TAF 15 den iSG 12 abhängigen Export von 
NR4A1 ins Zytoplasma. In einem fluorescence resonance energy transfer 
Experiment führte es überraschenderweise zu einer verstärkten Interaktion 
zwischen ISG 12 und NR4A1. Dies weist darauf hin, dass TAF 15 für die Interaktion 
möglicherweise nicht notwendig ist, es aber bereits entstandene Komplexe 
stabilisieren könnte. 
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1. Introduction 
 
 
1.1  Atherosclerosis 
 
Atherosclerosis is a cardiovascular disease, which is nowadays the most common 
cause of death in the developed world [1]. It is characterized by the World Health 
Organization as “a variable combination of changes in the intima of arteries 
consisting of the focal accumulation of lipids, complex carbohydrates, blood and 
blood products, fibrous tissue and calcium deposits, and associated with medial 
changes”. 
The continuous built-up of fatty materials on the inside of artery walls results in a 
chronic inflammatory response, leading to the accumulation of macrophages and 
the formation of plaques. 
Atherosclerosis starts already in early adolescence [2], but is asymptomatic in the 
beginning. Its progression is discontinuous and can stagnate at times, which is on 
the other hand accompanied by periods of rapid growth. The acceleration of plague 
formation is affected by obesity, gender, hypertension, hyperlipidemia, excessive 
uptake of saturated fats, diabetes mellitus, lack of physical exercise and genetic 
factors. In adulthood atherosclerosis is usually wide spread throughout the arterial 
system. Plaque formation results in a reduction of lumen diameter, thus leading to 
higher speeds of blood flow. This eventually leads to plaque rupture and clots inside 
the artery lumen over the ruptures. These clots mostly heal and form arterial 
stenoses which can result in stable syndromes like insufficient blood supply to 
tissue. The development of stenoses is chronic and progresses slowly, whereas the 
formation of a thrombus is an acute event. It is also caused by plague rupture and 
slows down blood flow rapidly, which can ultimately lead to myocardial infarction or 
stroke. 
Narrowing of the artery lumen also leads to artery enlargement, which can 
compensate for the reduction of lumen [3]. The recurring hypoxic stimuli can 
additionally induce the formation of collateral vessels, again counteracting the 
effects of vessel narrowing. However, if the artery enlargement becomes excessive, 
it can result in an aneurysm [4], which is a blood-filled dilation of a blood vessel 
caused by weakening of the vessel wall. 
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1.2  Atherosclerotic development and progression 
 
 
The composition of a normal blood vessel is made up of three distinct layers, 
separated by an internal and external tissue. Arteries and veins are similar in their 
design, but the three layers are better distinguishable in arteries. 
 
 
Figure 1.1: Schematic drawing of the different layers in veins and arteries [78]. 
 
 
The tunica intima, a thin endothelial monolayer, is the innermost layer of the blood 
vessel and has direct contact with the blood stream. It is structurally supported by 
the internal elastic lamina.  
The tunica media, a layer of smooth muscle cells, is responsible for maintaining the 
vascular tone. This layer is more developed in arteries than in veins. 
The tunica adventitia is seperated from the tunica media by the external elastic 
lamina and consists of fibroblasts, collagen bundles and proteoglycans. It is the 
outermost layer of the blood vessel [5]. 
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The vascular endothelium is responsible for regulating many important functions, 
including vascular tone, maintaining blood circulation, coagulation and fluidity. It is 
also involved in regulating inflammatory responses [16]. In a healthy vessel, white 
blood cells do not bind to the endothelium, it even acts against an adherence by 
secreting anti-coagulation mediators. 
But gene expression in endothelial cells can be altered by certain cardiovascular 
risk factors, such as hypertension, hyperglycaemia, hypertriglyceridemia and 
hypercholesterolemia. These risk factors lead to the expression of adhesion 
molecules on the endothelial surface. The most important adhesion molecules are 
the vascular cell adhesion molecule-1 (VCAM-1) and the inter-cell adhesion 
molecule-1 (ICAM-1) [11]. 
To trigger an inflammatory response lipoproteins, like low-density lipoprotein (LDL), 
have to be become oxidized. They accumulate in the intima of an artery where they 
bind to components of the extracellular matrix [9]. If the LDL concentration is high in 
the blood stream, more of it is bound and the chance of oxidation increases [17], 
leading to a variety of biologically active products, like lipid hydroperoxides, 
lysophospholipids and carbonyl compounds. 
These particles make up the so-called “fatty streaks”, the first step in atherosclerotic 
development [6]. These “fatty streaks” are often removed by an acute inflammatory 
response, but in some cases the acute response turns into a chronic inflammatory 
response. In this case the persistence of chronic inflammation is responsible for the 
progression of the disease, even though the triggering event is already terminated 
[7]. 
A result of the ongoing inflammatory response is the activation of transcription 
factors like NfkB and AP1 [8]. These transcription factors are now responsible for 
the expression of adhesion molecules like VCAM-1 and ICAM-1, as mentioned 
above. They are located at the endothelial surface and contact leukocytes. Other 
surface molecules including P-selectin, E-selectin, L-selectin and various integrins 
enable leukocytes to traverse the endothelial layer by diapedesis between cellular 
junctions.  
  9 
 
Figure 1.2: Different stages in leukocyte rolling and diapedesis. 
 
First leukocytes are slowed down by weakly binding to selectins, which results in a 
rolling adhesion. That is further improved by integrin binding and ICAM-1 binding. 
This directed migration of leukocytes is regulated by a chemoattractant gradient in 
the atheroma [10]. 
Monocytes that reach the intima differentiate to macrophages due to the 
macrophage colony stimulating factor (MCSF) that is produced there. 
 
 
Figure 1.3: Early stages of plague formation in the tunica intima. Differentiation of monocytes to 
macrophages and accumulation of modified LDL in foam cellls [27]. 
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Macrophages increasingly express scavenger receptors, like scavenger receptor A 
(SRA) or CD36 [13]. The expression of these receptors on the surface of 
macrophages results in the internalization of different forms of modified lipoproteins, 
like oxidized LDL. Lipoproteins are stored in cytoplasmic droplets, which lets 
macrophages swell as more and more lipoproteins are internalized. This leads to 
the formation of foam cells [14], which in turn secrete growth factors and cytokines. 
So the initial beneficial function of macrophages to clear the intima from modified 
lipoproteins is itself the next step towards plague formation. Growth factors and 
cytokines released from foam cells themselves act in a pro-inflammatory manner, 
increasing the recruitment of monocytes, macrophages, T lymphocytes and mast 
cells. Additionally they activate the classical and alternative complement pathway, 
stimulating the proliferation and migration of smooth muscle cells from the tunica 
media. These SMC form a fibrous capsule covering the “fatty streak”. Apoptosis of 
foam cells leads to the release of previously incorporated lipoproteins, which 
accumulate together with cell debris in a lipid rich centre of the plague.  
Adding to the ongoing plague formation are T lymphocytes, which also migrate into 
the intima. They are mostly Th1 cells and they contribute by releasing IL-2, TNFα, 
TNFβ and IFNγ. These cytokines stimulate pro-inflammatory cells already present in 
the atheroma. Furthermore they enhance proliferation of smooth muscle cells. Th2 
cells, which in general exhibit anti-inflammatory effects, play a minor role due to 
their lack of numbers [15]. 
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Figure 1.4: Distinct stages in the development of complicated lesions and corresponding time of 
onset. 
 
 
The accumulation of smooth muscle cells leads to the development of more 
complicated atheroma, which growing size significantly decreases the lumen of the 
vessel. First clinical manifestations arise when the blood flow gets disturbed.  
The fibrous capsule covering the plague is continuously degraded by collagenases 
that are produced by macrophages. Collagenase also inhibits the new synthesis of 
collagen by smooth muscle cells. As a result the capsule becomes thinner and the 
risk of rupture increases. Once the plague breaks open tissue factors of 
macrophages are released into the blood stream where they activate platelets, 
which in turn activate the system of coagulation which results in thrombus formation 
[12]. A thrombus is a complex structure of leukocytes, erythrocytes, platelets and 
fibrin as the final step of hemostasis. It can lead to myocardial infarction, stroke or 
critical limb ischemia. In the case of a nonlethal outcome, the following wound 
healing response again stimulates the proliferation of smooth muscle cells, further 
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narrowing the lumen of the blood vessel. 
Increased amounts of lipids in the blood are the starting point for atherosclerosis, 
but the critical step in its formation is the switch from an acute immune response to 
a chronic one. So in fact, the initial inflammatory response to clear oxidized LDL 
from the intima eventually leads to plague formation and the onset of disease. 
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1.3  Nuclear Receptors 
 
 
Nuclear receptors (NRs) are proteins found in animals where they act as 
transcription factors [19] in regulating gene expression. They are involved in the 
control of development, homeostasis, metabolism and reproduction. NRs bind to 
lipophilic molecule within the cell and in response work together with other proteins 
to induce a downstream effect in either up or down regulating the expression of 
specific genes. 
NRs themselves have the ability to directly bind to DNA, but first they need to be 
activated by a ligand. Ligand binding results in a conformational change in the 
receptor and a loss of corepressors. With the dissociation of corepressors NRs bind 
to coactivators which in turn can interact with the transcriptional machinery. 
Figure 1.5: Mechanism of transcriptional activation by the thyroid hormone receptor. 
 
All NRs consist of five domains. The N-terminal domain includes the activation 
function 1 (AF1) which is ligand independent [20]. It is involved in transactivation by 
interacting with co-regulators. The N-terminal regulatory domain is highly variable in 
sequence between different NRs. Adjacent to the N-terminus is the DNA binding 
domain (DBD), which is a highly conserved region. It is made up of two zinc fingers 
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which can bind to specific sequences of DNA called hormone response elements 
(HRE). The most commonly recognized sequence is 5'-PuGGTCA-3'. HRE 
sequences can consist of merely one such sequence, or of two copies as a 
palindrome or a direct repeat [18]. The DBD is linked to the ligand binding domain 
(LBD) via a flexible hinge region. The LBD is a moderately conserved region at the 
C-terminus of NRs. The LBD structure is a so-called alpha helical sandwich fold 
consisting of 8 alpha helices that make up the ligand binding cavity. In addition the 
LBD contributes to receptor dimerization. Finally the LBD contains the activation 
function 2 (AF2) at the C-terminal end of the receptor [20]. The function of AF2 is 
ligand-dependent contrary to AF1. 
 
 
Figure 1.6: Different structural domains common in nuclear receptors. 
 
 
NRs are divided in six subfamilies according to sequence homology [18]: 
 
Subfamily 1: Thyroid Hormone Receptor-like 
Is the largest subfamily and contains Thyroid hormone receptors (TR), 
Retinoic acid  receptors (RAR), Peroxisome proliferator-activated 
receptors (PPAR), Rev-ErbA,  RAR-related orphan receptors (ROR), Liver 
X receptor-likes (LXR) and Vitamin D  receptor-likes. 
Subfamily 2: Retinoid X Receptor-like 
 Contains Hepatocyte nuclear factor-4 (HNF4), Retinoid X receptors (RXR), 
 Testicular receptors (TR), TLX/PNR and COUP/EAR. 
Subfamily 3: Estrogen Receptor-like 
Also called steroid or sex hormone receptors, contains Estrogen receptors 
(ER),  Estrogen related receptors (ERR) and 3-Ketosteroid receptors 
(glucocorticoid  receptor, mineralocorticoid receptor, progesterone 
receptor and androgen receptor). 
Subfamily 4: Nerve Growth Factor IB-like 
Contains Nerve Growth factor IB (NR4A1 or Nur77), Nuclear receptor related 
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1 (NURR1) and Neuron-derived orphan receptor 1 (NOR1). 
Subfamily 5: Steroidogenic Factor-like 
 Contains Steroidogenic factor 1 (SF1) and Liver receptor homolog-1 (LRH-1). 
Subfamily 6: Germ Cell Nuclear Factor-like 
 Contains only Germ cell nuclear factor (GCNF). 
 
Figure 1.7: Phylogenetic tree of nuclear receptors. The subfamilies are indicated in brackets. The 
numbers display the bootstrap confidence in percentage [18]. 
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1.3.1   The NR4A Subfamily 
 
 
The NR4A Subfamily of nuclear receptors consists of three members, Nur77 also 
called NR4A1, TR3, NGFI-B or Nak1; Nurr1 also known as NR4A2 or NOT; and 
NOR-1 or indicated as NR4A3 or MINOR. They all comprise the same structural 
features as other NRs, which are mentioned above, but so far, no ligands have 
been identified. Therefore they are classified as orphan receptors. Crystallography 
of the ligand binding domain of Nurr1 revealed that the ligand binding pocket is filled 
with hydrophobic amino acid side chains [21]. This could mean that Nurr1 is 
completely unable to interact with ligands, but a possible induced fit of small 
unknown ligands cannot be excluded (for example C-DIMs or cytosporine). Due to a 
high homology in the LBDs of all three members a similar function is proposed for 
the LBDs of Nur77 and NOR-1. The DNA binding domain shows the highest 
homology of amino acid sequence with about 90%. This suggests an evolutionary 
relationship for the NR4A members and that they might descend form one ancestral 
gene. 
 
 
 
 
 
 
 
 
 
Figure 1.8: (a) Structural domains of NRs. (b) Amino acid sequence alignment of NR4A family 
members. Numbers give similarity in percent compared to Nur77.  
 
NR4A NRs bind with their DNA binding domain as monomers to the NGFI-B 
response element (NBRE, AAAGGTCA). They can also bind as homodimers to the 
Nurr1 response element (NurRE, TGATATTTn6AAATGCCA) which is an inverted 
repeat containing two NBRE related sequences separated by 6 nucleotides [22]. 
Besides, Nur77 and Nurr1, but not NOR-1, can heterodimerize with the retinoid X 
receptor (RXR, a member of NR Subfamily 2) and bind to the DR5 response 
element (AGGTTCACCGAAAGGTCA) [23]. 
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NR4A nuclear receptors are expressed in many different tissues in the human body 
and are involved in a variety of processes. Nur77 has been described in cancer cell 
apoptosis and Nurr1 has an essential role in brain development. They are described 
as “immediate early genes” because they are transiently and rapidly induced by a 
number of stimuli. These include inflammatory cytokines, growth factors, fatty acids, 
oxidized lipids and lipopolysaccharides (LPS) as well as physical stimuli. 
Transcription factors involved in activating NR4A NRs gene expression are cAMP 
response element binding protein (CREB), activator protein-1 (AP-1), myocyte 
enhancing factor-2 (MEF-2), nuclear factor of activated T-cells (NFAT) and NFκB 
[24] [25] [74]. In addition to gene expression also posttranslational modifications 
affect the transcriptional activity of NR4A NRs. NR4A receptors can be 
phosphorylated at either serines or threonines by the kinase Akt, the extracellular 
signal-regulated kinase 2 (ERK2) or the Jun N-terminal kinase. The phosphorylation 
of Nur77, for example, at serine-350 by Akt inhibits its DNA binding capacity, which 
leads to a down regulation of Nur77s transcriptional activity [26].  
In recent years, more and more publications have been published about the 
expression of all three NR4A members in human atherosclerotic lesions, fasted 
liver, skeletal muscle and adipose tissue [44].  
 
 
1.3.2 NR4A nuclear receptors in metabolic processes 
 
 
A dysregulated lipid and glucose mechanism are major risk factors for the 
development of vascular disease [28]. It has been shown that all three members of 
the NR4A Subfamily are induced in cultured mouse hepatocytes by glucagon [29]. 
This induction is mediated by CREB, a transcription factor for hepatic 
gluconeogenesis. After induction, Nur77 itself induces the expression of glucose-6-
phosphatase (G6pc) and fructose biphosphatase 1 (Fbp1), two gluconeogenic 
enzymes. Furthermore a couple of other proteins involved in glucose metabolism 
are also induced, like Fbp2, glucose transporter Glut2(Slc2a2) and enolase 3 
(Eno3). Additionally, overexpression of Nur77 in mouse liver resulted in an increase 
of gluconeogenesis and an increase of blood glucose after fasting [29]. 
Lipids and glucose are utilized in skeletal muscle cells for the generation of energy. 
The activation of adrenergic receptors by β-adrenergic receptor agonists induces 
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lipolysis in skeletal muscle cells. These agonists also induce increased expression 
of Nur77 and NOR-1 protein. When Nur77 is knocked down with siRNA it results in 
down regulation of several genes involved in lipolysis and energy expenditure, 
mainly glucose transporter 4 (Glut4), caveolin 3 (CAV3), CD36 and uncoupling 
protein 2 (UCP2). According to this, lipolysis is decreased in skeletal muscle cells 
upon inactivation of Nur77. NOR-1 and Nur77 have also been found to be 
expressed during myogenesis and knockdown of NOR-1 in skeletal muscle cells 
increases myostatin expression. So it is believed that NOR-1 is somehow involved 
in regulating skeletal muscle mass [30] [31]. 
 
 
1.3.3 NR4A nuclear receptors in macrophages  
 
 
Certain atherosclerotic stimuli, like oxidized LDL, LPS and TNF-α, induce the 
expression of NR4A nuclear receptors in monocytes and macrophages [32] [33] 
[34]. Nur77, Nurr1 and NOR-1 are all expressed in atherosclerotic lesion 
macrophages, especially in areas of plaque activation and remodeling. This 
indicates an involvement of NR4A family members in the progression of plaque 
formation [35]. 
Nur77 works as a pro inflammatory mediator in mouse macrophages by inducing I-
κ-B kinase (IKKi) [34]. Induction happens by direct binding of Nur77 to the NBRE 
sequence in the promoter region of the IKKi gene. On the other hand, it was also 
shown that an up regulation of NR4A receptors in cultured human THP-1 derived 
macrophages leads to a reduction in the expression of inflammatory cytokines, like 
IL-1β, IL-6 and IL-8 [35]. Other proteins downregulated in response to NR4A 
receptor over-expression are the monocyte chemoattractive protein-1 (MCP-1), the 
macrophage inflammatory protein (MIP)-1α and MIP-1β. Furthermore an over-
expression leads to a decreased uptake of oxidized LDL particles into 
macrophages, because of a reduced expression of CD36 and scavenger receptor 
SR-A, thus slowing down the formation of foam cells. Accordingly, a knock down of 
Nur77 or NOR-1 results in increased inflammatory cytokine production and an 
enhanced uptake of oxidized LDL. The effect on the inflammatory gene expression 
is believed to be due to the ability of NR4A NRs to transrepress NFκB. It has been 
shown that Nur77 down regulates the transcriptional activity of NFκB [36]. 
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1.3.4 NR4A nuclear receptors in VSMC 
 
 
Vascular smooth muscle cells are normally quiescent contractile cells that are 
responsible for maintaining vessel wall stability. In the case of local inflammation or 
vascular damage, they become activated and start to migrate into the intimal 
compartment of the vessel wall, where they start proliferating. 
Expression of NR4A NRs was first observed after the stimulation of SMCs with 
conditioned media from oxidized LDL activated macrophages. Nur77 was induced 
in the murine vessel wall only 6 hours after a cuff-induced SMC-rich lesion 
formation [37] [38]. This is in accordance to the characterization of NR4A NRs as 
“immediate early genes”. After examining human patients it became evident that 
NR4A NRs are expressed in activated SMCs in atherosclerotic lesions and other 
related vascular pathologies like vein-graft disease. 
SMCs obtained from NOR-1 deficient mice showed repressed proliferation after 
activation [39]. Data sustained by a knock down of NOR-1 in SMCs using antisense 
oligonucleotides showed similar results. Decreased proliferation is accompanied by 
a decrease in expression of cell cycle proteins cyclin D1 and cyclin D2. 
On the other hand, Nur77 shows an inhibitory effect on SMC proliferation, unlike 
NOR-1. In this case, an over expression of Nur77 in venous and arterial SMCs 
leads to a reduced proliferation [38]. Mice that express a dominant-negative variant 
of Nur77 lacking the N-terminal transactivation domain, show enhanced lesion 
formation upon carotid artery ligation. The dominant negative form of Nur77 blocks 
the transcriptional activity of all three members of the NR4A subfamily. Reduced 
proliferation of SMCs is accompanied by an up regulation of the cell cycle inhibitor 
p27Kip1 and a decrease in the cell cycle protein cyclin A [37] [38]. 
Additional experiments revealed a connection between over-expression of Nur77 
and the expression of calponin and smooth muscle α actin, suggesting that Nur77 
might induce an even more differentiated SMC phenotype [38]. 
Endogenous NR4A NRs seem to protect against the formation of atherosclerotic 
plaques, since mice over-expressing Nur77 in the arterial vessel wall show 
decreased lesion formation and mice over-expressing the dominant negative variant 
of Nur77 develop larger lesions. 
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1.3.5 NR4A nuclear receptors in ECs 
 
 
NR4A NRs are induced in endothelial cells upon stimulation with VEGF, TNF-α or 
IL-1β [41] [42] [43]. VEGF stimulation also results in a decreased phosphorylation of 
Nur77 in ECs at the negative regulatory site serine-350 [42]. 
The only directly regulated gene by Nur77 is the plasminogen activator inhibitor 1 
(PAI-1), which is an important inhibitor of vascular fibrinolysis. Nur77 binds directly 
to an NBRE sequence in the promoter of the PAI-1 gene, inducing PAI-1 
expression. Again, cells expressing a dominant negative form of Nur77, show 
almost no PAI-1 expression even when stimulated with TNF-α [44]. 
Knock down of NOR-1 in ECs results in decreased proliferation and migration upon 
VEGF stimulation. Also silencing of Nur77 leads to a decrease in VEGF-induced 
proliferation [43].  
Over-expression of Nur77 accordingly enhanced EC survival and proliferation, 
together with an induction of cyclin A, cyclin D1, proliferating cell nuclear antigen 
(PCNA) and transcription factor E2F. 
Finally, it was shown that the levels of Nur77 are increased in ECs during 
angiogenesis. Consistent with those findings, angiogenesis was reduced in Nur77 
deficient mice, also reducing tumor cell growth. 
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1.4 ISG 12 
 
 
The interferon-stimulated gene 12 (ISG 12) was primarily found to be an estrogen-
induced gene, but was later found to be mainly stimulated by type I IFNs [48]. 
IFNs mediate their biological functions mainly through the activation of ISGs. More 
than 1000 ISGs have been found till now [45], and their activation starts with the 
binding of IFN to specific cell surface cytokine receptors. After IFN is bound the 
receptor chains oligomerize and the nonreceptor tyrosine kinases Janus kinases 
(Jak 1-3) and tyrosine-specific kinase (Tyk) phosphorylate each other as well as 
tyrosine residues on the receptor chains. The kinases, once activated, 
phosphorylate signal transducers and activators of transcription proteins (STATs). 
The activated STATs move to the nucleus and act as transcription factors [46]. 
There are two different IFN signaling pathways. Type I IFNs cause STAT1 and 
STAT2 to heterodimerize and to associate with the DNA-binding protein IFN 
regulatory factor-9 (IRF-9). Together they form the IFN-stimulated gene factor 3 
(ISGF3) complex, which can bind to the IFN-stimulated response element (ISRE) in 
the promoter region of type I IFN stimulated genes. Type II IFN however leads to a 
homodimerization of STAT1, forming the IFN-γ activated factor (GAF). GAF binds to 
IFN-γ activation sites (GAS) in the promoter region of type II IFN stimulated genes 
[47]. 
Figure 1.9: Activation of STATs by IFN and the formation of functional transcription factors. 
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ISG 12 is part of the so called “small ISGs”, it encodes a putative hydrophobic 
protein with 122 amino acids. Its molecular weight is approximately 12 kDa. As 
mentioned above it was first found as an estrogen-induced gene in human breast 
adenocarcinoma cells [48]., however the expression of ISG 12 did not correlate with 
the presence of estrogen receptors in other cells. Still two estrogen receptor 
elements were found upstream of the IFN-regulated elements in the ISG 12 
promoter region. Further studies revealed that ISG 12 is highly up regulated by type 
I IFNs [49], especially IFNα, in cells irrespective to their estrogen receptor status, 
indicating that IFNα inducibility is estrogen independent. This is consistent with the 
human gene 6-16, which together with ISG 12 is a member of the ISG 12 gene 
family. In total there are 46 members from 25 organisms belonging to the ISG 12 
gene family [50]. 
 
Figure 1.10: Phylogenetic tree of the ISG 12 family. Two stars represent a bootstrap confidence level 
>85%, one star >60% [50]. 
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The proteins of the ISG 12 family are encoded by the GIP3 and IFI27 genes. The 
ISG 12 gene is located on chromosome 14q32 with a length of approximately 6kb 
[48] [51]. Four members of the family were found in human, ISG 12(a), ISG 12(b), 
ISG 12(c) and 6-16. 6-16 is located on chromosome 1p35. Another three were 
found in mice coding for 90 amino acid long proteins with a molecular weight of 
approximately 10 kDa. 
 
Figure 1.11: Genomic organisation of ISG12 genes in humans and mice. Regions of human 
chromosomes 1p35 and 14q32, and mouse chromosome 12F1, carrying ISG12 genes are shown. 
Transcribed regions are coloured. Translational initiation and termination sites are indicated by green 
and red circles, respectively. Exons encoding an ISG12 motif are starred. 
 
Human ISG 12 has 5 different splice variants of its mRNA encoding for full length 
protein [52]. There is a shorter splice variant lacking exon 2, leading to a short 
isoform of ISG 12, called ISG 12-S [75]. Furthermore there is ISG 12∆, which has a 
9-nt deletion in exon 4. The deletion is in frame and causes a loss of 3 amino acids. 
The combined isoform ISG 12-S∆ lacks an additional 5 amino acids in its N-terminal 
region compared to ISG 12-S. Finally the mRNA of ISG 12 has two different 5' UTR 
splice variants, both encoding a full length ISG 12 protein. 
 
ISG 12 is inserted into the nuclear envelope [52] and it is possible that it is an 
inducible part of the nuclear pore complex. 
It is expressed in a variety of normal tissue like kidney, colon, prostate, placenta, 
ovaries, testis and endothelium and also in tumors from skin [53] [54], colon, 
pancreas, kidney, breast and lung. 
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In recent years, Papac-Milicevic, N. et al. studied the functions of ISG 12 as a 
modulator in atherosclerosis and restenosis in vitro and in vivo [56].  
ISG 12 was found as an interaction partner of the nuclear receptor NR4A1 in a 
yeast two hybrid system and was later found to be up regulated 4-times in human 
atherosclerotic lesions, compared to adjacent non-afflicted areas [56]. Furthermore 
ISG 12 was expressed upon IFNα stimulation in the monolytic cell line U937, in 
VSMCs and in human umbilical vein endothelial cells (HUVECs). 
First in vitro experiments showed that ISG 12 has the ability to down regulate the 
transcriptional activity of several nuclear receptors, including NR4A1, NR4A2, 
PPARα, PPARγ, LXR and FXR. The inability of ISG 12 to affect the transcriptional 
activity of NR4A3 led to the assumption that ISG 12 is selective for NRs that can 
form heterodimers with RXR. 
The down regulating effect of ISG 12 was found to be due to an export of NRs out 
of the nucleus. These results were first obtained by over-expressing ISG 12 and 
EGFP-tagged NR4A1 in HEK cells and were later confirmed in mouse embryonic 
fibroblasts (MEFs) by increasing the amount of endogenous ISG 12 by IFNα 
stimulation. Additionally no nuclear export of NR4A1 was seen in ISG 12 deficient 
MEFs. The same results applied for PPARα [56]. 
Regarding these results and since ISG 12 is located in the nuclear envelope close 
to nuclear pore complexes, it is highly likely that ISG 12 binds to NRs and 
decreases their nuclear localization by influencing their export to the cytoplasm.  
 
ISG 12 deficient mice as well as wild type mice were thereafter subjected to carotid 
artery ligation and femoral artery cuff experiments [56]. In WT mice, the experiments 
led to a high up regulation of ISG 12, NR4A1 and monocyte attractant protein 1 
(MCP-1), an inflammatory marker gene. On the other hand, knock out mice showed 
no narrowing of the vessel lumen and no up regulation of MCP-1. This effect 
possibly involves NR4A1, since NR4A1 and ISG 12 double deficient mice 
developed restenosis similar to WT mice. Consistent with in vitro data, the 
localization of NR4A1 in the nucleus was reduced in WT mice in ligated arteries 
compared to ISG 12 knock out mice. 
 
All this data suggests that the beneficial effect in ISG 12 deficient mice is due to the 
protective transcriptional activity of nuclear receptors.  
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1.5 TET Family 
 
 
TAF 15 together with TLS and EWS are members of the TET family [57]. All 
members of this unique family are RNA-binding proteins and are structurally and 
functionally closely related. They share an N-terminal SYGQ-rich region, an RNA-
recognition motif, a zinc finger motif and at least one RGG-repeat region [58].  
The TET family proteins have all been found in a whole set of cancer associated 
fusion genes, for example TAF 15 – CIZ/NMP4 [62] from acute leukaemia or TAF 15 
– CHN/TEC [63] [64] from extraskeletal myxoid chondrosarcoma. In all cases the N-
terminus of either TLS, EWS or TAF 15 acts as a transcriptional activation domain 
and is fused to an DNA-binding domain of a transcription factor [59] [60] [61]. These 
newly formed transcription factors are believed to be involved in the formation of a 
variety of different cancers. In some of these fusions TLS, EWS and TAF 15 can 
replace each other with out changing the resulting pattern of gene expression, 
suggesting a functional relationship. 
 
 
 
Figure 1.12: An interaction map for TLS [79] 
 
 
The TET proteins are some of the few proteins found to be able to bind directly to 
RNA as well as single stranded and double stranded DNA [75] [76] [77]. Given their 
abilities it is not surprising that they were found to be involved in splicing [65] and 
RNA shuttling [66] [67]. However these proteins have also been implicated in the 
process of gene transcription. 
TAF 15 is part of the basal transcription factor TFIID and therefore associated with 
the formation of the pre-initiation complex [68]. TFIID is essential for the initiation of 
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transcription by RNA polymerase II, by binding to the core promoter and serving as 
a scaffold for the assembly of the remaining complex. TFIID consists of the TATA-
binding protein (TBP) and of several TBP-associated factors, TAFs [69]. 
TLS and EWS can interact with several gene-specific transcription factors, which 
probably gives them a more specialized role in regulating gene expression. TLS is 
additionally an interaction partner for a couple of nuclear hormone receptors like 
RXR or estrogen receptor [70]. It was also found to interact with the p65 subunit of 
NFκB, a key regulator of apoptosis [71]. 
 
All three members can furthermore interact with transcriptional repressors, like 
ZFM1 [72], showing that they all are very versatile parts in the initiation or 
repression of transcription. 
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2. Objectives 
 
 
 
Previous research done by Nikolina Papac-Milicevic et al [56] revealed an 
involvement of ISG 12 in the development of atherosclerosis. ISG 12 was found to 
downregulate the transcriptional activity of the nuclear receptor NR4A1 almost 
completely. By cloning different deletion constructs of ISG 12, Sabine Fenzl tried to 
find the direct interaction site between ISG 12 and NR4A1. Unfortunately no 
conclusive results could be obtained. 
The objective of my work was to identify other interaction partners of ISG 12 and to 
investigate whether they are somehow involved in the regulation of nuclear receptor 
activity. 
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3. Results 
 
 
3.1 Tandem Affinity Purification Results 
 
 
To find interaction partners of ISG 12, I tagged myc-ISG 12 with a Tandem Affinity 
Purification (TAP) [73] tag at the C-Terminus. The resulting C-TAP tagged myc-ISG 
12 was stably transfected into HEK293 cells and cultivated. One hundred 175cm2 
flasks were harvested and the cells were lysed. After all the tandem purification 
steps were completed (see materials & methods) the purified protein complexes 
were analyzed by mass spectroscopy. 
The identified interaction partners of ISG 12 are listed in figure 3.1. Common false 
positive results are removed. 
 
 
INTERACTION 
PARTNER 
LOCALIZATION RELEVANCE 
BASP1 Nucleus and 
membrane 
Associate with WT1 to regulate ist 
transcription function during development. 
FLJ22594 Cytoplasm 
(cytoskeleton) 
Targets myosin phosphatase to the actin 
cytoskeleton. 
CACNA2D1 Membrane L-type calcium channel, regulates cell 
metabolism and proliferation. 
CD109 Membrane GPI-glycoprotein, part of TGF-βreceptor 
system in human keratinocytes, upregulated 
in tumors. 
CDC42BPA Cytoplasm Required for cell invasion through the 
regulation of MLC2 phosphorylation. 
CD55 Membrane GPI-glycoprotein, interruption by CD55 of 
the complement sequence at an early step 
in activation halts progression of the 
cascade and prevents consequent cell 
injury. 
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FYN Membrane Tyr kinase, required in brain development 
and mature brain function and regulation of 
axon growth. 
GLG1 Golgi apparatus 
membrane 
GLG1 might have a chaperone function, 
perhaps playing a role in processing and 
targeting the growth factor in the cell.  
LIMA1 Cytoplasm Colocalizes with actin stress fibers and focal 
adhesion plaques. 
MARCKSL1 Membrane May be involved in coupling the PKC and 
calmodulin systems. 
PPP1R12A Cytoplasm It is one of the subunits and integral 
component of the myosin phosphatase. 
RAI14 Nucleus and 
cytoplasm 
Highly expressed in several cancer cell 
lines, precise function remains to be 
determined. 
TAF15 Nucleus and 
cytoplasm 
RNA, dsDNA and ssDNA binding protein 
that might play specific roles during 
initiation at distinct promoters 
TLS Nucleus and 
cytoplasm 
RNA, dsDNA and ssDNA binding protein 
that might play specific roles during 
initiation at distinct promoters 
Figure 3.1: List of positive interaction partners of ISG 12 found by a tandem affinity purification and 
analyzed by mass spectroscopy. 
 
 
TAF 15 and TLS, both members of the TET family, were the most promising 
candidates for further investigation, since they were already known to interact with 
certain nuclear receptors, likewise ISG 12. Additionally, TAF 15 is a part of the basal 
transcription factor TFIID, which is essential for the initiation of transcription by RNA 
polymerase II. ISG 12 might in some way interfere with the formation of the pre-
initiation complex by binding and retaining TAF 15 and TLS. 
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3.2 Confirmation of Tandem affinity purification results 
 
To confirm that TAF 15 actually forms a complex with ISG 12, I performed a Co-
Immunoprecipitation using an anti-myc antibody to pull down myc-ISG 12. The 
following Western blot was developed with an anti-TAF 15 antibody. The obtained 
band from the CoIP had the same size as the band from a cell lysate (control for 
Input) and was missing in a negative control. For the negative control I used an 
unspecific rabbit IgG antibody for the pull-down. 
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Figure 3.2: Western blot bands from a 10% SDS-Page gel plotted on a PVDF membrane. The 
membrane was developed with an anti-TAF 15 polyclonal antibody and labelled with a corresponding 
secondary peroxidase labelled antibody. WHC stands for whole cell lysate. 
 
 
To further investigate the colocalization between TAF 15 and ISG 12, I transfected 
HEK293 cells in 2 Well chamberslides with myc-ISG 12. The cells were incubated 
with primary antibodies against myc and TAF 15 and labelled with fluorescent 
secondary antibodies. Pictures were taken with a LSM-510 Meta confocal laser 
microscope. 
ISG 12 was labelled green with Alexa Fluor 488 and TAF 15 was labelled red with 
Alexa Fluor 568. A possible colocalization would lead to yellow fluorescence due to 
colour interference. 
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Figure 3.3: Representative confocal microscope image of TAF 15 (red) and ISG 12 (green). 
(n=3; each time at least 20 images were taken) 
 
 
3.3 Influence of interferon α on the expression of TAF 15 
 
 
Since ISG 12 is highly upregulated by type I IFNs and especially by IFNα, and since 
TAF 15 and TLS are also stress induced genes like ISG 12, I tested smooth muscle 
cells (SMC), HEK293 cells and human umbilical vein endothelial cells (HUVECS) 
for TAF 15 expression after IFNα stimulation. 
RNAs were isolated after stimulation with 1000U/ml IFNα for 0.5 hours, 1.5 hours, 
3.5 hours, 5.5 hours and 7.5 hours. Reverse transcribed cDNAs were amplified in a 
Roche Diagnostics LightCycler and gene expression was normalized to PBGD. 
No significant up or downregulation of TAF 15 with IFNα was detected in tested 
cells. Variations in the expression levels of TAF 15 at the different time points may 
be the result of other IFNα induced mechanisms in the cell. But TAF 15 itself does 
not seem to be induced in an IFNα dependent manner. 
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Figure 3.4: Time course for the expression of TAF 15 after stimulation with 1000U/ml IFNα in 
HEK293, HUVECs and SMCs. (n=3) 
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3.4 Influence of TAF 15 on the transcriptional activity of NR4A1 
 
 
As already mentioned before, ISG 12 has the ability to almost completely abolish 
the transcriptional activity of NR4A1. To see whether TAF 15, as a newly identified 
ISG 12 partner, has an effect on the transcriptional activity of NR4A1, I performed a 
reportergene assay overexpressing NR4A1 and silencing TAF 15 with its mRNA 
specific siRNA. Scrambled RNA was used as a control. The promoter of the 
Luciferase reporter gene contained four NBREs and SV40 renilla was used as an 
internal standard. 
Custom designed siTAF 15 was previously tested in HEK293 cells and real-time 
PCR results proof that TAF 15 is actually downregulated by this siRNA by 80%. 
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Figure 3.5: (a) Reportergene Assay for the transcriptional activity of NR4A1 using TAF 15 siRNA and 
scrambled RNA. (b) Real-time PCR to show the silencing effect of si TAF 15. 
 
 
NR4A1 upregulates the expression of the reporter gene approximately seven fold 
when at the same time treated with scrambled RNA. Silencing TAF 15 does not 
have any effect on this upregulation, suggesting that TAF 15 itself does not 
influence the transcriptional activity of NR4A1. 
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3.5 Interactions of TAF 15 with transcription factors 
 
 
We already knew that ISG 12 forms complexes with a variety of nuclear receptors, 
like NR4A1, RXRα and PPARα as well as other factors like p65, one part of the 
heterodimeric transcription factor NFκB. Furthermore, TLS, a family member of the 
TET family, was also already published to interact with several nuclear receptors. 
The possibility that ISG 12 actually forms a complex with these proteins together 
with TAF 15 could not be excluded. First I performed Co-Immunoprecipitations to 
look for interactions between TAF 15 and the previously named transcription 
factors, to see whether TAF 15 interacts with NRs similar as TLS. The transcription 
factors were overexpressed by a transient transfection of their expression vectors 
and used for the pull down. TAF 15 was only present at endogenous levels. TAF 15 
was also detected in the cell lysate, aliquoted before the immunoprecipitation, as a 
positive control. 
 
WB: αTAF15
IP:    p65
NR4A1
RXRα
PPARα
− + − − − − − −
− − − + − − − −
− − − − − + − −
− − − − − − − +
WHC WHC WHC WHCIP IP IP IP
 
Figure 3.6: CoIPs between p65, NR4A1, RXRα, PPARα and TAF 15. The indicated transcription 
factors were used to pull down TAF 15. The Western blot was developed with a TAF 15 polyclonal 
antibody. Negative controls were performed using unspecific IgGs (data not shown). (n=4) 
 
 
 
All four transcription factors show a positive CoIP with TAF 15, which indicates a 
major role of TAF 15 in the regulation of gene expression induced by these factors. 
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3.6 Influence of TAF 15 on complex formation between ISG 12 and 
transcription factors 
 
 
To investigate whether TAF 15 has an influence on the complex formation between 
ISG 12 and certain transcription factors, I again performed several Co-
Immunoprecipitations. The transcription factors were again used to pull down 
protein complexes, but this time I detected ISG 12 on a Western blot in either 
presence or absence of siTAF 15. 
The detected Western blot bands were normalized to the respective ISG 12 bands 
from the cell lysates (not shown). The experiment was repeated three times and the 
quantified results were merged together to calculate statistical significance. 
Quantifications were done using the Imager analysis software (Alpha Innotech 
Corporation, USA). 
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Figure 3.7: (a) Immunoreactive bands of mycISG 12, after pull-downs with P65, RXRα, PPARα and 
NR4A1. (b) Differences in band intensity comparing scrambled RNA and siTAF15. The 
immunoreactive bands were normalized to corresponding bands from cell lysates (not shown).  
(n=3, ttest p<0.05) 
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All but PPARα show a statistically significant reduced complex formation when TAF 
15 is silenced by siRNA. 
 
 
3.7 Effect of TAF 15 on the nuclear export of NR4A1 
 
 
Nikolina Papac Milicevic et. al. previously showed that ISG 12 exhibits at least a 
part of its downregulating effect on the transcriptional activity of NR4A1 by 
mediating its export from the nucleus to the cytoplasm. The complete mechanism 
behind this effect is still not completely clarified. Since ISG 12 and TAF 15 form a 
complex with each other as well as with NR4A1, I looked whether the effect of ISG 
12 on the translocation of NR4A1 is TAF 15 dependent or not.  
I transiently transfected HEK293 cells in 2 well chamberslides with EGFP-NR4A1 
and ISG 12 for immuno-histochemistry. Pictures were taken with an Olympus AX-70 
microscope and cytoplasmic NR4A1 was quantified. As in previously performed 
experiments, siTAF 15 was used to silence endogenous TAF 15, whereas 
scrambled RNA was used as a negative control. 
 
GFP-NR4A1 GFP-NR4A1+ISG12
scrambled 
siTAF-15
 
 
Figure 3.7: Microscopy pictures of HEK293 cells, transiently transfected with GFP-NR4A1 and ISG 
12. NR4A1 is shifted into the cytoplasm when cotransfected with ISG 12, but remains in the nucleus 
when TAF 15 is silenced at the same time. (n=3 experiments, representative pictures) 
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Figure 3.9: Quantification of cytoplasmic NR4A1 in transiently transfected HEK293 cells. 
(n=3) 
 
 
Confirming the previously obtained data from Nikolina Papac Milicevic et. al., 
approximately 40% of NR4A1 present in the cell were located in the cytoplasm 
when co-transfected with ISG 12. When NR4A1 is transfected alone, only 
approximately 20% of NR4A1 are found in the cytoplasm. 
In the case of TAF 15 silencing, a co-transfection of ISG 12 doesn’t change the 
observed outcome. In both cases, no matter whether ISG 12 is overexpressed or 
not, only about 15% of NR4A1 is located in the cytoplasm, indicating an 
involvement of TAF 15 in translocation of NR4A1. The exact mechanism of this 
effect is still unknown, but this experiment shows that TAF 15 is very likely involved 
in the exporting effect of ISG 12 on transcription factors. 
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3.8 FRET on NR4A1 and ISG 12 under the influence of TAF 15 
 
 
To further investigate the complex formation between NR4A1 and ISG 12, I carried 
out a fluorescence resonance energy transfer (FRET) between them. I again used 
siRNA against TAF 15 to look whether TAF 15 is involved in this complex formation. 
 
green channel red channel FRET channel FRET index
EGFP-NR4A1 + ISG 12 + si TAF 15
green channel red channel FRET channel FRET index
EGFP-NR4A1 + ISG 12 + scr
 
 
Figure 3.10: Microscopy pictures of HEK 293 cells, overexpressing EGFP tagged NR4A1 and myc 
tagged ISG 12. The green channel shows the EGFP-NR4A1 donor signal at an emission wavelength 
of 512 nm. The red channel shows the Alexa 568 labeled ISG 12 acceptor signal at an emission 
wavelength of 603 nm. The FRET channel shows the signal measured with the acceptor emission 
wavelength when excited with the donor excitation wavelength of 488 nm. The FRET index was 
afterwards calculated by subtracting the bleed through of both the donor and the acceptor channel.   
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Figure 3.11: Quantification of the FRET signal between overexpressed GFP-NR4A1 and ISG-myc, 
treated with either scrambled RNA or siTAF 15. (n=3) 
 
 
In this case, silencing of TAF 15 led to an increased interaction of NR4A1 and ISG 
12. Whereas silencing of TAF 15 in Co-Immunoprecipitation experiments led to a 
diminished interaction. Since the interaction in CoIP experiments was not 
completely abolished (band still present, but with reduced intensity), it suggests that 
ISG 12 and NR4A1 can interact partially in a TAF 15 independent way. On the other 
hand, microscopy results show that TAF 15 is definitely necessary to mediate the 
ISG 12 dependent export of NR4A1 from the nucleus to the cytoplasm. This could 
mean that TAF 15 stabilizes the NR4A1-ISG 12 complex. 
This is also a possible way to explain the increased FRET signal when TAF 15 is 
silenced. The lack of TAF 15 probably changes the way in which ISG 12 binds to 
NR4A1, possibly bringing the Donor and the Acceptor, necessary for the resonance 
transfer, closer together and thus increasing the signal.  
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4. Conclusion 
 
 
ISG 12 is a small interferon induced protein, located in the nuclear membrane. It 
was found previously to be responsible for the downregulation of the transcriptional 
activity of several nuclear receptors, by mediating their export into the cytoplasm. To 
better understand the mechanism of this effect I was looking for new interaction 
partners of ISG 12 that might help us to better understand its role in the cellular 
machinery. 
After evaluating possible interaction partners of ISG 12, obtained from the Tandem 
Affinity Purification System, TAF 15 and TLS were the first studied in the ISG 12 
dependent regulation of transcriptional activity of nuclear receptors. 
Concentrating on TAF 15, I primarily confirmed the rightness of the Tandem Affinity 
Purification System with Co – immunoprecipitation experiments in HEK293 cells 
and furthermore verified the colocalization of the two proteins with immuno -
histochemistry images. 
Furthermore I analyzed a possible change of expression of TAF 15 after an 
interferon stimulation, because IFNα is a major ISG 12 inducer, but no upregulation 
of TAF 15 on the mRNA level could be observed. This could be explained by the 
fact that TAF 15 is part of the basal transcriptional machinery and its role in the 
formation of the RNA polymerase II pre-initiation complexes is obligatory. In the 
case of a possible mechanism involving both TAF 15 and ISG 12, it is feasible that 
ISG 12 is the limiting factor. So upregulation of ISG 12 by interferon stimulation 
could enhance the complex formation with TAF 15 since it is already present in 
sufficient quantity. 
ISG 12 downregulates the transcriptional activity of nuclear receptors by facilitating 
their export from the nucleus as already mentioned above. I did not find such an 
effect for TAF 15, since the transcriptional activity of NR4A1 was not affected when 
TAF 15 was silenced. 
Both TLS and TAF 15 interact with ISG 12 and since TLS interacts with several 
nuclear receptors, I was interested if TAF 15 does the same. All tested NRs plus 
p65 were found positive to interact with TAF 15 as well as with ISG 12. The possible 
connection between the three components was revealed in the consequent 
experiment, showing significantly weaker interactions between ISG 12 and the 
different transcription factors when TAF 15 was silenced. Furthermore the export of 
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NR4A1 influenced by ISG 12 was found to be TAF 15 dependent, suggesting that 
TAF 15 is necessary for ISG 12 to mediate its effect. 
On the other side, FRET revealed that silencing of TAF 15 led to an increased 
complex formation of NR4A1 and ISG 12. The possible mechanism suggested by 
these results is that TAF 15 may stabilize the interaction between NR4A1 and ISG 
12 and by doing so helps ISG 12 to induce the export, but is not itself implicitly 
necessary for the formation of the NR4A1-ISG 12 complexes. 
Since ISG 12 deficient mice were found to survive better in carotid artery ligation 
models, contrary to NR4A1 knock out mice, which showed a reduced life 
expectancy, it would be very interesting to fully understand the physiological 
interaction between these two proteins. With the performed experiments I can show 
that TAF 15 is definitely involved in this interplay, but the exact mechanism is yet to 
be resolved. 
 
Outlook: 
 
To further study the involvement of TAF 15 in the regulation of nuclear receptors, I 
would like to clone TAF 15 into an expression vector for use in reporter assays and 
protein microarrays. A TAF 15 deficient cell line could make the results on complex 
formation more significant, since siRNA never leads to a complete knock out of TAF 
15. 
To get more details on the complex formation involving TAF 15, ISG 12 and nuclear 
receptors it would be very helpful to conduct an IP over an IP, but so far I was not 
able to do this. 
Furthermore I am interested to see if TAF 15 also influences the export of other 
nuclear receptors like it does with NR4A1. Finally I would like to analyze if the other 
TET family members exhibit the same effects as TAF 15. 
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5. Methods 
 
 
5.1 Cell Culture 
 
 
Human Embryonic Kidney cells (HEK293) were obtained form ATCC (Manassas, 
VA) and cultured in 75cm2 flasks at 37°C with 5% CO 2 in DMEM (Dulbecco's 
modified Eagle's medium (Sigma, St.Louis, MO)) plus 1% L-glutamine, antibiotics 
and 10% foetal bovine serum. 
To split the cells, media was removed and 10ml of calcium-magnesium free Hank’s 
medium (CMFH) were added. Afterwards the cells were detached with 5 ml of 
trypsin. After 5 minutes trypsinization was stopped by the addition of 20ml of Hank’s 
balanced salt solution (HBSS). Cells were pelleted down and resuspended in 10ml 
of DMEM. The cellsupension was then added in the appropriate amount to either 6 
well plates, 12 well plates or chamberslides for further experiments and to another 
75 cm2 flask for further cultivation. 
 
 
5.2 Transient transfection of HEK293 with Calcium-Phosphate 
 
 
HEK293 cells were transiently transfected with calcium-phosphate for Co– 
Immunoprecipitations, Reporter Assays and Immuno Histochemistry experiments. 
1.5µg DNA per well were used in 12 Well plates and 2 well chamberslides and 3µg 
DNA per well in 6 well plates. DNA was mixed with dH2O (distilled and deionized) 
and CaCl2 and added drop-wise to the same amount of HeBS Buffer. The 
transfection mix was then incubated for 3 minutes at room temperature. Afterwards 
the DNA-precipitate was added to the cells. Transfected cells were at least 
incubated for 24 hours. 
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5.3 Dual – Luciferase Reporter Assay 
 
 
5.3.1 Principle 
 
Dual Reporter Assays are a common tool to study eukaryotic gene expression. 
They are especially useful to study promoter activity and the influence of 
transcription factors.  
In this system two different reporter enzymes are used at the same time. First the 
activity of Firefly Luciferase is measured. The emitted light is based on the enzymes 
activity to decarboxylize luciferin. 
 
 Luciferin + ATP + O2 → oxyluciferin + AMP + PPi + CO2 + light 
 
The second part of the assay is the measurement of Renilla Luciferase as a 
standard. To be able to measure Renilla Luciferase, the Firefly Luciferase reaction 
is terminated by Stop & Glo. 
 
Coelenterazine + O2 → Coelenteramide + CO2 + light 
 
As the amount of luminescence produced by Firefly Luciferase is directly 
proportional to the expression of our target promoter, the activity of Renilla 
Luciferase is not. So the activity of our target promoter is normalized to the internal 
control (Renilla) to minimize experimental variability due to differences in 
transfection efficiency and cell viability. 
 
 
5.3.2 Reporter Assay 
 
HEK293 cells were grown in 12 wells to approximately 60 – 70% confluence and 
then transfected with Firefly and Renilla Luciferases using the Calcium-Phosphate 
Method. After 24 hours of incubation the cells were lysed using 1x Passive Lysis 
Buffer (Promega, Wisconsin) for 30 minutes at room temperature. 20µl lysate was 
transferred from each well to a luminometer plate.  
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The Luciferase Assay Reagent and the Stop & Glo Reagent (Promega, Wisconsin) 
were prepared according to the manufacturer's instructions, 50µl per sample were 
used. 
The luminescence was then measured   by a Wallac Victor luminometry machine 
(Perkin Elmer, MA). 
All experiments were performed in triplicates and repeated at least 3 times. 
 
 
5.4 Co – Immunoprecipitation 
 
 
5.4.1 Principle 
 
The Co – Immunoprecipitation is a method used to find protein – protein 
interactions. One antibody, specific for a certain protein is used to bind its target 
protein, and all other proteins that are attached to it are precipitated together as a 
complex, bound to sepharose beads. Those beads are used to pellet down the 
protein complex. After dissociation from the beads proteins from that complex with 
the target protein can be detected in a Western blot. 
 
 
5.4.2 Protocol 
 
HEK293 cells were transfected in 6 Wells using the Calcium-Phosphate Method. 
After 24 hours incubation the cells were lysed for 30 minutes in a buffer containing 
2.7mM KCl, 1.5mM KH2PO4, 9.2mM Na2HPO4.2H2O, 150mM NaCl, 0.7% NP40, 
0.3% Triton X-100 and protease inhibitor (Roche Diagnostics, Switzerland). 
Samples were centrifuged for 15 minutes at 15.000 x g and the supernatant was 
incubated for 1 hour at 4°C with 2 µg of the appropriate antibody. The precipitation 
was also performed with unspecific IgGs, as a negative control. Protein A sepharose 
beads (Amersham Biosciences, UK) were added and the samples incubated for 2.5 
hours at 4°C. Beads were washed 5 times with PBS an d then resupended in 2x 
Lämmli-Buffer. After 10 minutes at 95°C the superna tant was transferred into new 
tubes and the beads were discarded. Samples were finally subjected to Western 
Blot. 
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5.5 Western Blot 
 
 
After the Co - immunoprecipitation the samples were subjected to 10% and 12% 
SDS-polyacrylamide gel electrophoresis. Gels where then transferred to a 
polyvinylidene difluoride membrane (PVDF) (Millipore, Bedford, MA). Membranes 
were than blocked for 1 hour using either 5% milk or 3% bovine serum albumin 
(BSA) in phosphate buffered saline (PBS) containing 0.1% Tween 20. The 
corresponding primary antibody was added directly to the blocking solution for over 
night incubation, in a concentration according to the manufacturer’s 
recommendation. Afterwards membranes were incubated for 1 hour with the 
corresponding secondary peroxidase labeled antibodies (Amersham Biosciences, 
UK). ECL Plus (Amersham Biosciences, UK) was used to detect immunoreactive 
bands. 
 
 
5.6 TAP – Tandem Affinity Purification 
 
 
5.6.1 Principle 
 
The Tandem Affinity Purification System is a well established tool to purify protein 
complexes under native conditions. The TAP Method requires the attachment of the 
TAP tag, to either the C-Terminus or the N-Terminus of the protein of interest, in our 
case myc-ISG 12. After stably transfecting HEK293 cells with the TAP tagged myc-
ISG 12, those cells are cultivated and harvested in huge quantities. The cell extracts 
containing the fusion protein as well as associated partners are recovered by two 
specific affinity purification steps. Gathered protein complexes can then be analyzed 
by mass spectrometry. 
The TAP tag consists of two IgG binding units of protein G from Streptococcus sp. 
and the streptavidin – binding peptide, separated by a TEV – protease cleavage 
site. 
First protein complexes are pulled down by IgG sepharose and then released by 
TEV – protease cleavage. Cleaved proteins are furthermore bound to streptavidin 
sepharose and in the end eluted with biotin. 
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5.6.2 Protocol 
 
5.6.2.1 Vector generation (Gateway Cloning) 
 
The first step in generating the expression vector for TAP tagged myc-ISG 12 was 
to amplify ISG12 from an already existing plasmid. The PCR reaction mix 
contained: 
 1µl  template 
 1µl  Forward primer 
 1µl  Reverse primer 
 5µl  10x PCR buffer 
 5µl  dNTPs 
 3.5µl  MgCl2 
 33µl  ddH2O 
 0,5µl  KOD polymerase (Novagen) 
 
Forward primer: 5´GGGG ACA AGT TTG TAC AAA AAA GCA GGC TAG ACT GCC 
ATG GCA TCA ATG CAG AAG CTG 3´ 
Reverse primer: 5´GGGG AC CAC TTT GTA CAA GAA AGC TGG GTT GTA GAA 
CCT CGC AAT GAC AGC 3´ 
 
 Following thermocycler settings were used: 
 
 98°C  2 minutes 
 
19x 98°C  15 seconds 
 55°C  5 seconds 
 72°C  30 seconds 
 
 68°C  10 minutes 
 
KOD polymerase added the Gateway attB1 and attB2 sequences to the 5' and the 
3' end of our gene of interest. The PCR product was subsequently subjected to a 
1.5% Agarose gel electrophoresis and stained with 3% ethidiumbromid. 
The wanted DNA band was then cut out of the agarose gel with a scalpel under UV-
light and transferred to an Eppendorf tube. DNA was isolated with the QIAEX II 
gelextraction kit (Qiagen, Valencia, USA). The band was weighted and 3 volumes of 
buffer QX1 and 20µl QIAEXII reagent were added. The following purification steps 
were done according to the manufacturer's protocol. 
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The purified DNA fragment was then introduced into the Gateway Donor vector 
using the BP Reaction. 
 1µl  PCR product 
 1µl  Donor Vector 
 2µl  BP buffer plus BP Reaction Enzym 
 6µl  dH2O 
 → 1 hour incubation at room temperature. 
 
The enzyme mix catalyzed the recombination and insertion of the attB sequence 
containing PCR product into the attP recombination sites in the Gateway Donor 
vector. After the insertion the new vectors were called Entry vectors. 
The resulting Entry vectors containing myc-ISG 12 were transformed into competent 
E. coli. Therefore 15µl E. coli were mixed with 10µl of the BP Reaction and put on 
ice for 20 minutes. Afterwards the E. coli were heatshocked at 42°C for 45 seconds 
and put back on ice immediately for 2 minutes. The transformed bacteria were then 
incubated in 500µl SOC media at 37°C for 30 minutes. 
The whole mixture was plated on LB agar plates containing 50µg/ml kanamycin and 
incubated at 37°C over night. 
5 colonies were picked and inoculated into 2 ml of LB medium containing 
kanamycin. After 24 hours of incubation at 37°C the  bacteria were harvested and a 
minikit was performed (Eppendorf Fast Plasmid Mini-Prep Kit) according to the 
manufacturer's protocol. 
A restriction digestion was performed as a control to see whether the DNA fragment 
of interest was actually inserted into the Entry vector. 
 10µl  plasmid  
 1µl  BsrG1 restriction enzyme 
 5µl  NE Buffer2 
 34µl  dH2O 
 → 2 hours incubation at 37°C with shaking at 400 rpm . 
 
The restricted samples were applied to an 0.8% agarose gel electrophoresis and 
the presence of the insert was confirmed. 
 
The LR Reaction was done to attach the TAP tag to the C-terminus of ISG12. Again 
utilizing the Gateway Cloning System the LR Reaction contained: 
 2µl  Clonase mix plus Buffer 
 0,8µl  prV CTAP 
 0,4µl  Entry clone 
 6,8µl dH2O 
 → 1 hour incubation at room temperature 
The Destination vector prV CTAP contained an expression promoter and the C-
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terminal TAP tag. It was kindly provided by the lab of G. Superti-Furga. 
The ISG12-TAP cassette was then cloned into a Moloney murine leukemia virus-
based vector, which was stably transfected into HEK293 cells and successfully 
transfected cells were selected by FACS analysis. This was performed by Mag. Ines 
Kaupe at the Research Center for Molecular Medicine.  
One hundred 175cm2 flasks were grown and the harvested cells were subjected to 
the affinity purification steps. 
 
 
5.6.2.2 Affinity purification 
 
Frozen cells were put on ice and resuspended with lysis buffer containing 50mM 
Tris/HCl, pH7.5, 5% glycerol, 0.2% NP-40, 1.5mM MgCl2, 25mM NaF, 100mM NaCl, 
1mM Na3VO4 and protease inhibitors. Cells were then incubated on ice for 30 
minutes and centrifuged for 15 minutes at 15.000 x g at 4°C. Previously washed IgG 
beads (Amersham Biosiences. UK) were added to the supernatant and incubated at 
4°C for 2 hours. After incubation the beads were pe lleted down and transferred into 
a column (0,8ml Mobicol). Columns were washed with lysis buffer and with TEV 
Buffer containing 10mM Tris/HCl, pH 7.5, 100mM NaCl, 0.5mM EDTA, 0.2% NP-40 
without protease inhibitors. 
360µl TEV buffer plus 40µl TEV protease were added to the columns and incubated 
for 1 hour at 16°C. Then the TEV – eluate was allow ed to drop out by gravity flow 
into an Eppendorf tube. Another 400µl of TEV cleavage buffer was added to the 
columns and emptied by applying pressure (syringe). 
Streptavidin beads were washed with TEV buffer and the bead suspension was 
then added to new Mobicol columns. The liquid dropped out by gravity flow. 
TEV – eluate was added to the streptavidin beads and incubated for 1 hour at 4°C. 
The eluate dropped out by gravity flow and the beads were washed with TEV buffer. 
Afterwards 400µl Biotin elution buffer containing a tip of biotin diluted in 5ml 10mM 
Tris/HCl, pH 7.5, 10mM NaCl were added to the streptavidin beads and incubated 
for 5 minutes at 16°C. Again the eluate was allowed  to drop out by gravity flow into 
an Eppendorf tube. This step was repeated once more. 
The eluates were then frozen in liquid nitrogen and lyophilized over night. After that 
the samples were send to mass spectrometry analysis. 
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5.7 siRNA silencing 
 
 
5.7.1 Principle 
 
siRNA stands for small interfering RNA and is a popular mechanism to transiently 
silence a specific gene. It acts in the RNAi pathway by binding specifically to its 
mRNA target. 
The RNAi pathway is usually initiated by the enzyme Dicer, which cleaves long 
double-stranded RNAs (dsRNA) into approximately 20 nucleotide long fragments. 
One of the two strands of each fragment is then incorporated into the RNA-induced 
silencing complex (RISC). The RISC complex then helps the siRNA to bind to its 
specific mRNA and induces cleavage by Argonaute, the catalytic component of the 
RISC complex. The cleaved mRNA is subsequently degraded and no protein 
product is formed, thus gene silencing occurs on a post-transcriptional level. In our 
case the used siRNA anti TAF15 (Ambion, Austin, USA) was already single 
stranded and ready to use. Corresponding scrambled RNA was used as a control. 
 
 
5.7.2 PEI Transfection 
 
 
5.7.2.1 Principle 
 
PEI transfection was used to transfect HEK293 cells successfully with siRNAs. This 
method is based on polyethylenimine, which condenses the RNA into positivley 
charged particles. Nitrogens form ionic interactions with the phosphate groups on 
the RNA backbone. Those particles are taken up by the cell via endocytosis, the 
rising osmotic pressure in the endosomes causes them to burst eventually, 
releasing the siRNAs into the cytoplasm. 
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5.7.2.2 Protocol 
 
HEK293 cells were seeded the day before in 12 Well plates and grown to 
approximately 50% confluence. 
Before starting to prepare the transfection mixes, PEI reagent was at least vortexed 
for 1 minute at full speed. For one 12 well plate 554,4µl HeBS Buffer were mixed 
with 24µl of either siRNA (50µmol) or scrambled RNA (50µmol) in an Eppendorf 
tube. 554,4µl HeBS Buffer and 37µl PEI reagent were mixed separately in a second 
Eppendorf tube. Then the two solutions were added together and incubated at room 
temperature for 20 minutes. During the incubation time cells were washed twice 
with serum free DMEM medium. Afterwards 90µl of the transfection mix were added 
to 400µl of serum free DMEM and put on the cells. 
After 3 hours of incubation at 37°C the media was e xchanged to 500µl pre-warmed 
DMEM full (containing 1% L-glutamine, antibiotics and 10 % foetal bovine serum). 
 
On the following day cells could be transfected with plasmids of interest using the 
same technique. In that case 1µg DNA was transfected per well. 
 
 
5.8 Immuno Histochemistry 
 
 
For immuno histochemistry experiments cells were seeded in 2 well chamberslides 
(Labtek, Rochester, USA), which were precoated with gelatine for 15 minutes at 
37°C. 1 µg DNA was transfected in each well on a 2 well chamberslide, using the 
Calcium – Phosphate method. 
After over night incubation the cells were fixed with 4% paraformaldehyd (PFA) for 
25 minutes at room temperature. PFA was removed and the cells were washed 
twice with 1x PBS. Permeabilization was done using 0.3% Triton X–100 in 1x PBS 
for 20 minutes at room temperature. Washing was repeated and the cells were 
blocked in 1% BSA in 1x PBS for 1 hour at room temperature. 
The primary antibody was added directly into the blocking solution and incubated 
over night at 4°C. After washing the secondary anti body was added again in 1% 
BSA in 1x PBS and incubated for 1 hour at room temperature. Secondary 
antibodies bind to the constant Fc-portion of the primary antibodies and are labeled 
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with certain fluorophores, which make them detectable in a fluorescence 
microscope.   
Then the cells were stained for 5 minutes with DAPI and afterwards the slides were 
mounted with coverslips using geltol. 
To confirm specificity of antibodies, additional coverslides were used, stained 
without primary antibodies (data not shown). 
Thereafter images were taken on an Olympus AX-70 microscope. 
 
 
5.9 FRET 
 
 
5.9.1 Principle 
 
Fluorescence resonance energy transfer (FRET) is a physical process by which 
energy is transferred nonradiatively from one excited fluorophore (the donor) to 
another fluorophore (the acceptor). This process is distance-dependent and 
happens by means of intermolecular long-range dipole-dipole coupling. The 
combination of a cyan fluorescent protein (CFP) and a yellow fluorescent protein 
(YFP) is a very commonly used technique. In this case, excitation of the donor 
molecule (CFP) results in emission from the acceptor molecule (YFP). This 
mechanism is dependent on the distance between the two. Only if they are close 
enough (5-10nm) energy transfer will occur. Therefore FRET is a very useful 
method to monitor direct protein-protein interactions in living or fixed cells. 
 
Figure 5.1: Schematic drawing of a fluorescence resonance energy transfer 
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5.9.2 Protocol 
 
HEK cells were transfected and treated like for other immunohistochemistry 
experiments. To be able to measure a FRET signal, pEGFP-NR4A1 and ISG12-myc 
were transfected. ISG12-myc was then labeled with Alexa 568 fluorescent antibody 
in a 1:200 dilution (Molecular Probes, Oregon). 
Images were then taken on a LSM-510 Meta confocal laser microscope (Zeiss, 
Germany) at 488 nm excitation and 512 nm emission wave length (505 – 530 nm 
filter for NR4A1) and separated from the Alexa 568 fluorescent label at 543 nm 
excitation and 603 nm emission wave length (585 – 615 nm filter for ISG12-myc).  
 
 
5.10 mRNA quantification 
 
 
5.10.1 RNA isolation 
 
HEK293 cells, SMC and HUVECs were grown in 6 Well plates and stimulated with 
1.000U/ml IFNα. After the stimulation the cells were harvested by removing the 
medium and application of 500µl QUIAzol to each well. The cells were then 
incubated for 5 minutes and subsequently transferred into 1.5ml Eppendorf tubes. 
200µl of RNAse free chloroform were added and the tubes were incubated for 3 
minutes at room temperature after vortexing. Afterwards the tubes were centrifuged 
at 4°C for 15 minutes at full speed. After the cent rifugation the aqueous phase of 
each sample was transferred into a new tube and mixed with 500µl RNAse free 
isopropanol. The samples were again incubated at room temperature for 10 
minutes. To precipitate the RNA the samples were centrifuged at 4°C for another 10 
minutes at full speed. The supernatants were removed and discarded. The pellets 
were washed with 1ml of RNAse free 75% ethanol and centrifuged for 30 minutes at 
4°C at full speed. The supernatant was again discar ded and the pellets were put at 
50°C in a heating block to dry. Afterwards the samp les were diluted with 50µl of 
RNAse free water and again incubated at 50°C for 10  minutes. 
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5.10.2 Reverse Transcription 
 
The concentration of the isolated RNA was measured and adjusted to a final 
concentration of 3µg/µl with RNAse free water. 900ng RNA were then used to run 
the reverse transcription PCR, using following reaction mix: 
  
 3 µl RNA template 
 1 µl Oligo d(T)16 
 2 µl 10x PCR Buffer II 
 4 µl 25mM MgCl2 
 8 µl dNTPs 
 1 µl RNAse Inhibitor 
 1 µl MuLV Reverse Transcriptase 
 
Following standard thermocycler program was used: 
 
 20°C  10 minutes 
 42°C  15 minutes 
 99°C  5 minutes 
 
 
5.10.3 Real-time PCR 
 
5.10.3.1 Principle 
 
Real-time PCR is generally used to amplify and at the same time quantify cDNAs 
that were previously reverse transcribed from isolated mRNAs. Real-time PCR is a 
very useful tool to study gene expression on the level of mRNA. 
In the case of real-time PCRs the DNA concentration is actually measured in real 
time. This is made possible by a dsDNA fluorescent dye like SYBR green. The dye 
only fluorescents when bound to dsDNA, and its fluorescence is measured after 
each cycle. The measured values of the target gene are then normalized to 
housekeeping genes. Housekeeping genes are believed to be equally expressed in 
various different tissues and are therefore suitable to be used as references. 
Commonly used housekeeping genes are glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), β-2-microglobulin (β2M), porphobilinogen deaminase 
(PBGD), albumin, actins or tubulins. 
At some point the measured fluorescence exceeds a threshold value of background 
fluorescence. This point is called the crossing point and it appears as a steep rise of 
the curve on the experiments fluorescence chart. With a higher starting cDNA 
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concentration the crossing point is reached after less cycles and vice versa. That 
means that the number of cycles to reach the crossing point can be used to 
calculate the relative starting amount of cDNA used. 
 
5.10.3.2 Protocol 
 
cDNA was used from the previously performed reverse transcription of isolated 
mRNA. The final concentration of cDNA corresponded to an amount of 2,5ng total 
RNA. Each sample was loaded into a capillary together with 1.5 µl DNA Master Mix, 
1.8 µl 25mM MgCl2, 10.1 µl H2O and 0.4 µl of each primer (10 µM). PBGD was 
used as a housekeeping gene. Following standard PCR program was used: 
  
 1x  10 minutes   95°C 
 55x 5 seconds   95°C 
  15 seconds   65°C 
  15 seconds   72°C 
 
TAF 15 forward primer: 5’ TGC AAT GAG CCT AGA CCA GA 3’ 
TAF 15 reverse primer: 5’ CCC ACT TCT ATC TCC GCT GT 3’ 
PBGD forward primer: 5’ TCG AGT TCA GTG CCA TCA TC 3’ 
PBGD reverse primer: 5’ CAG GTA CAG TTG CCC ATC CT 3’ 
 
 
5.11 Statistics 
 
 
Experimental values are expressed as mean ± SEM if not otherwise indicated. 
Statistical significances were determined by unpaired Student’s t-test. Significance 
was assigned to a value of p<0.05. 
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6. Materials 
 
6.1 Reagents 
 
si TAF 15 Ambion, Austin, USA 
scr RNA Ambion, Austin, USA 
ECL Plus Western Blotting Detection Amersham Biosciences, Buckinghamshire, 
UK 
Human Embryonic Kidney 293 cells ATCC, Manassas, USA 
Triton X-100 Bartelt, Graz, Austria 
L-Glutamine BioWhittaker Europe, Essen, Germany 
PSF BioWhittaker Europe, Essen, Germany 
Trypsin BioWhittaker Europe, Essen, Germany 
Seakem GTGR agarose Biozym, Oldendorf, Germany 
Fast Plasmid Mini Kit Eppendorf, Hamburg, Germany 
Gene Ruler 1 kbp DNA ladder Fermentas, Hanover, USA 
Gene Ruler 100 bp DNA ladder Fermentas, Hanover, USA 
Ethidium bromide Gibco, Carlsbad, USA 
Alexa Fluor 488 Invitrogen, Carlsbad, USA 
Alexa Fluor 568 Invitrogen, Carlsbad, USA 
BP buffer plus BP reaction enzyme Invitrogen, Carlsbad, USA 
LB broth Invitrogen, Carlsbad, USA 
Protein A Sepharose beads Invitrogen, Carlsbad, USA 
Protein G Sepharose beads Invitrogen, Carlsbad, USA 
Chloroform Merck, Darmstadt, Germany 
Ethanol Merck, Darmstadt, Germany 
KOD Polymerase Merck, Darmstadt, Germany 
Protease Inhibitor Merck, Darmstadt, Germany 
PVDF Membrane Immobilon-P Millipore Corp., Billerica, USA 
BsrG1 restriction enzyme New England BioLabs, Frankfurt, Germany 
NE buffer2 New England BioLabs, Frankfurt, Germany 
Streptavidin beads New England BioLabs, Frankfurt, Germany 
Plasmid Midi Kit Qiagen, Valencia, USA 
QIAEX II Agarose Gel Extraction Kit Qiagen, Valencia, USA 
QIAzol Reagent Qiagen, Valencia, USA 
QX 1 Qiagen, Valencia, USA 
Fetal bovine serum Panserin 
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10x PCR buffer II Perkin Elmer, Wellesley, USA 
25mM MgCl2 Perkin Elmer, Wellesley, USA 
dNTPs Perkin Elmer, Wellesley, USA 
MuLV Reverse Transcriptase Perkin Elmer, Wellesley, USA 
Oligo d(T)16 Perkin Elmer, Wellesley, USA 
RNAse Inhibitor Perkin Elmer, Wellesley, USA 
50x Stop & Glo Substrate Promega, Madison, USA 
Luciferase Assay Buffer II Promega, Madison, USA 
Luciferase Assay Substrate Promega, Madison, USA 
5x Passive Lysis Buffer Promega, Madison, USA 
Stop & Glo Buffer Promega, Madison, USA 
Interferon α PromoCell, USA 
10x PCR Buffer + MgCl2 Roche-Diagnostics, Basel, Switzerland 
Fast Start DNA Master SYBR Green Roche-Diagnostics, Basel, Switzerland 
Light Cycler Capillaries Roche-Diagnostics, Basel, Switzerland 
MgCl2 Roche-Diagnostics, Basel, Switzerland 
Agar Sigma-Aldrich, St. Louis, USA 
CMFH Sigma-Aldrich, St. Louis, USA 
DMEM Sigma-Aldrich, St. Louis, USA 
HBSS Sigma-Aldrich, St. Louis, USA 
Hepes Sigma-Aldrich, St. Louis, USA 
Isopropanol Sigma-Aldrich, St. Louis, USA 
XL 1 blue Stratagene, Cedar Creek, USA 
Smooth Muscle Cells Technoclone, Vienna, Austria 
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6.2 Prepared Reagents 
 
Ampicillin 50g/l 
Biotin Elution Buffer tip of biotin 5ml Tris/HCl 10mM, pH 7.5 
Blotting Buffer 
250ml 4x Running Buffer 
200ml Methanol 
550ml dH2O 
Buffer C 6.06g Tris, pH 6.8 
up to 100ml dH2O 
CaCl2 
29.4g CaCl2x2H2O, 2M 
up to 100ml dH2O 
filter-sterilized 
CoIP Lysis Buffer 
2.7mM KCl 
1.5mM KH2PO4 
9.2mM Na2HPO4.2H2O 
150mM NaCl 
0.7% NP40 
0.3% Triton X-100 
protease inhibitors 
HeBS 
8g NaCl 280mM 
0.1034g Na2HPO4 1.5mM 
6.5g Hepes 50mM, pH 7 
up to 500ml dH2O 
filter-sterilized 
2x Laemmli Buffer  
12.5ml Buffer C 
5ml β-Mercaptoethanol 
2g SDS 
5ml brom phenole blue 
LB-Amp Agar plates 
10g LB broth 
7.5g Agar 
50µl/l Ampicillin 
up to 500ml dH2O 
Kanamycin 500µg/l 
4% Paraformaldehyde 
0.4g paraformaldehyde 
10ml PBS 
200µl KOH 
heat up to 60°C 
10x PBS 
400g NaCl 
10g Kcl 
12g KH2PO4 
72g Na2HPO4.2H2O 
up to 5l dH2O, pH 7.4 
PBST 0.1% Tween-20 in PBS 
  58 
4x Running Buffer 
12g Tris 
57.6g Glycerol 
4g SDS 
up to 1l dH2O 
SOC Medium 
0.5g LB broth 
62.5µl 1M Kcl 
250µl 1M MgCl2 
250µl 1M MgSO4 
500µl 1M glucose 
25ml dH2O 
Stripping Buffer 
12.5ml Buffer C 
5ml 20% SDS 
350µl β-mercaptoethanol 
up to 50ml dH2O 
TAE Buffer 40mM Tris-acetate 10mM EDTA 
TAP Lysis Buffer 
50mM Tris/HCl, pH 7.5 
5% glycerol 
0.2% NP40 
1.5mM MgCl2 
25mM NaF 
100mM NaCl 
1mM Na3Vo4 
protease inhibitor 
TEV Buffer 
10mM Tris/HCl, ph 7.5 
100mM NaCl 
0.5mM EDTA 
0.2% NP40 
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6.3 Machines 
 
 
8. Alpha Innotech (San Leandro, CA, USA) FluorChem HD2 Imaging System 
9. Amersham Biosciences (Buckinghamshire, UK) Ultrospec 3100pro 
Photometer 
10. Bandelin (Berlin, Germany) Sonopuls UW2070 
11. Bio-Rad Laboratories (Hercules, CA, USA) Power supply 1000 / 500 
12. Eppendorf (Hamburg, Germany) Mastercycler ep gradient 
13. Eppendorf (Hamburg, Germany) Mastercycler ep gradient S 
14. Eppendorf (Hamburg, Germany) Centrifuge 5415D 
15. Eppendorf (Hamburg, Germany) Centrifuge 5417C 
16. Genomatix Software GmbH (Munich, Germany) MatInspector© 7.4.8 
17. Hitachi Europe GmbH (Dusseldorf, Germany) U-2000 Spectrophotometer 
18. MWG Biotech (Ebersberg, Germany) UV-transilluminator 
19. Olympus (Hamburg, Germany) AX – 70 microscope 
20. Pharmacia (Uppsala, Sweden) Biotech Electrophoresis chamber 
21. Roche Diagnostics (Basel, Switzerland) LightCycler 
22. Sorvall (Kendro, Newtown, CT, USA) Centrifuge RC 26 Plus 
23. Wallac (Perkin Elmer, Wellesley, MA, USA) Victor2 1420 Multilabel Counter 
24. Zeiss (Germany) LSM – 510 Meta confocal microscope 
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